Quince Therapeutics (QNCX) Research & Development (2018 - 2026)

Quince Therapeutics has reported Research & Development for 9 years, with the latest figure at $5.5 million in Q2 2026.

• On a quarterly basis, Research & Development fell 16.66% year-over-year to $5.5 million in Q2 2026; TTM through Jun 2026 was $33.0 million, a 29.68% increase from a year earlier, with the FY2025 full-year figure at $35.4 million, up 90.33% from the prior year.
• Research & Development was $5.5 million for Q2 2026 at Quince Therapeutics, down from $6.8 million in the prior quarter.
• The five-year high for Research & Development was $12.8 million in Q1 2022, with the low at $1.4 million in Q2 2023.
• Average Research & Development over 5 years is $5.8 million, with a median of $5.5 million recorded in 2026.
• The sharpest annual moves came in 2022 and 2024: Research & Development plunged 82.54% in 2022, then jumped 243.54% in 2024.
• Over 5 years, Research & Development stood at $7.2 million in 2022, then sank by 52.32% to $3.4 million in 2023, then surged by 69.63% to $5.8 million in 2024, then soared by 116.33% to $12.6 million in 2025, then tumbled by 56.66% to $5.5 million in 2026.
• The last three Research & Development figures came in at $5.5 million (Q2 2026), $6.8 million (Q1 2026), and $12.6 million (Q4 2025), per Business Quant data.